Although IL-1 family cytokines are a potent nasal vaccine adjuvant involved against infectious diseases, the combination of IL-1 cytokines with commercial adjuvant (MF59 or alum adjuvant) is an effective pathway to induce both humoral and mucosal immune response against pathogens entering the mucosal layer [204]. This evidence concerns the gene IL1B and infectious disease.